menu
    • menu
    [{"orgOrder":0,"company":"US WorldMeds","sponsor":"Supernus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Apomorphine Hydrochloride","moa":"D2\/D3\/D4\/D5 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"US WorldMeds","amount2":0.53000000000000003,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0.53000000000000003,"dosageForm":"Subcutaneous Injection","sponsorNew":"US WorldMeds \/ Supernus Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"US WorldMeds \/ Supernus Pharmaceuticals"},{"orgOrder":0,"company":"US WorldMeds","sponsor":"Supernus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Apomorphine Hydrochloride","moa":"D2\/D3\/D4\/D5 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"US WorldMeds","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0.53000000000000003,"dosageForm":"Subcutaneous Injection","sponsorNew":"US WorldMeds \/ Supernus Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"US WorldMeds \/ Supernus Pharmaceuticals"},{"orgOrder":0,"company":"US WorldMeds","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Eflornithine Hydrochloride","moa":"ODC","graph1":"Oncology","graph2":"Approved FDF","graph3":"US WorldMeds","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"US WorldMeds \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"US WorldMeds \/ Inapplicable"},{"orgOrder":0,"company":"US WorldMeds","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Eflornithine Hydrochloride","moa":"ODC","graph1":"Oncology","graph2":"Approved FDF","graph3":"US WorldMeds","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"US WorldMeds \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"US WorldMeds \/ Inapplicable"},{"orgOrder":0,"company":"US WorldMeds","sponsor":"Norgine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Eflornithine Hydrochloride","moa":"ODC","graph1":"Oncology","graph2":"Approved FDF","graph3":"US WorldMeds","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"US WorldMeds \/ Norgine","highestDevelopmentStatusID":"15","companyTruncated":"US WorldMeds \/ Norgine"},{"orgOrder":0,"company":"US WorldMeds","sponsor":"Adaptimmune Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Acquisition","leadProduct":"Afamitresgene Autoleucel","moa":"MAGE-A4","graph1":"Oncology","graph2":"Approved FDF","graph3":"US WorldMeds","amount2":0.089999999999999997,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.089999999999999997,"dosageForm":"Intravenous Infusion","sponsorNew":"US WorldMeds \/ US WorldMeds","highestDevelopmentStatusID":"15","companyTruncated":"US WorldMeds \/ US WorldMeds"},{"orgOrder":0,"company":"US WorldMeds","sponsor":"Adaptimmune Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Acquisition","leadProduct":"Afamitresgene Autoleucel","moa":"MAGE-A4","graph1":"Oncology","graph2":"Approved FDF","graph3":"US WorldMeds","amount2":0.089999999999999997,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.089999999999999997,"dosageForm":"Intravenous Infusion","sponsorNew":"US WorldMeds \/ US WorldMeds","highestDevelopmentStatusID":"15","companyTruncated":"US WorldMeds \/ US WorldMeds"}]

    Find Clinical Drug Pipeline Developments & Deals by US WorldMeds

    Menu

    US WorldMeds

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            US WorldMeds

                            U.S.A arrow
                            ACS Fall 2025
                            Not Confirmed

                            US WorldMeds

                            U.S.A arrow
                            ACS Fall 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Afamitresgene Autoleucel

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Recipient : Adaptimmune Therapeutics

                            Deal Size : $85.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            US WorldMeds Completes Acquisition of Adaptimmune's Cell-Therapy Portfolio

                            Details : US WorldMeds gains access to Tecelra (afamitresgene autoleucel), lete–cel, afami–cel, and uza–cel. Tecelra is a medicine, called a genetically modified autologous T cell immunotherapy.

                            Product Name : Tecelra

                            Product Type : Cell and Gene therapy

                            Upfront Cash : $55.0 million

                            August 04, 2025

                            Lead Product(s) : Afamitresgene Autoleucel

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Recipient : Adaptimmune Therapeutics

                            Deal Size : $85.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            US WorldMeds

                            U.S.A arrow
                            ACS Fall 2025
                            Not Confirmed

                            US WorldMeds

                            U.S.A arrow
                            ACS Fall 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Afamitresgene Autoleucel

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Recipient : Adaptimmune Therapeutics

                            Deal Size : $85.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Cell Therapy Biotech Keeps Adapting, Selling 4 Programs for $55M

                            Details : US WorldMeds gains access to Tecelra (afamitresgene autoleucel), lete–cel, afami–cel, and uza–cel. Tecelra is a medicine, called a genetically modified autologous T cell immunotherapy.

                            Product Name : Tecelra

                            Product Type : Cell and Gene therapy

                            Upfront Cash : $55.0 million

                            July 28, 2025

                            Lead Product(s) : Afamitresgene Autoleucel

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Recipient : Adaptimmune Therapeutics

                            Deal Size : $85.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            US WorldMeds

                            U.S.A arrow
                            ACS Fall 2025
                            Not Confirmed

                            US WorldMeds

                            U.S.A arrow
                            ACS Fall 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Eflornithine Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            US WorldMeds Announces FDA Approval of IWILFIN™ (eflornithine) to Strengthen Fight Against Aggressive Childh...

                            Details : Iwilfin (eflornithine) is an ornithine decarboxylase inhibitor used to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma (HRNB).

                            Product Name : Iwilfin

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 14, 2023

                            Lead Product(s) : Eflornithine Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            US WorldMeds

                            U.S.A arrow
                            ACS Fall 2025
                            Not Confirmed

                            US WorldMeds

                            U.S.A arrow
                            ACS Fall 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Eflornithine Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FDA Approves Eflornithine for Adult and Pediatric Patients with High-Risk Neuroblastoma

                            Details : Iwilfin (eflornithine) is an ornithine decarboxylase inhibitor used to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma (HRNB).

                            Product Name : Iwilfin

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 14, 2023

                            Lead Product(s) : Eflornithine Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            US WorldMeds

                            U.S.A arrow
                            ACS Fall 2025
                            Not Confirmed

                            US WorldMeds

                            U.S.A arrow
                            ACS Fall 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Eflornithine Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Norgine

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Norgine Enter Agreement to Commercialise DFMO in Independent States

                            Details : DFMO is a repurposed molecule investigated for use as an extended maintenance treatment for high-risk neuroblastoma (HRNB) in paediatric patients with no active disease (NAD) / no evidence of disease (NED) after first line multiagent, multimodality thera...

                            Product Name : Iwilfin

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            July 23, 2021

                            Lead Product(s) : Eflornithine Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Norgine

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            US WorldMeds

                            U.S.A arrow
                            ACS Fall 2025
                            Not Confirmed

                            US WorldMeds

                            U.S.A arrow
                            ACS Fall 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Apomorphine Hydrochloride

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Supernus Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Supernus Completes Acquisition of CNS Portfolio from US WorldMeds

                            Details : This acquisition significantly expands Supernus' business in CNS and increases and diversifies its revenue and earnings streams, while continuing to maintain a strong balance sheet.

                            Product Name : Apokyn

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            September 06, 2020

                            Lead Product(s) : Apomorphine Hydrochloride

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Supernus Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            US WorldMeds

                            U.S.A arrow
                            ACS Fall 2025
                            Not Confirmed

                            US WorldMeds

                            U.S.A arrow
                            ACS Fall 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Apomorphine Hydrochloride

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Supernus Pharmaceuticals

                            Deal Size : $530.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Supernus to Acquire CNS Portfolio from US WorldMeds

                            Details : Acquisition adds three products developed and sold in the U.S. market with a late-stage development candidate in the Supernus pipeline: APOKYN ®, MYOBLOC ® XADAGO ® and Apomorphine Infusion Pump.

                            Product Name : Apokyn

                            Product Type : Other Small Molecule

                            Upfront Cash : $300.0 million

                            April 28, 2020

                            Lead Product(s) : Apomorphine Hydrochloride

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Supernus Pharmaceuticals

                            Deal Size : $530.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth